Bongseo Choi
Overview
Explore the profile of Bongseo Choi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi H, Choi B, Kim D
Biomaterials
. 2024 Oct;
314:122902.
PMID: 39454505
Anaerobic bacteriolytic cancer therapy, whether delivered locally or systemically, frequently encounters challenges related to limited colonization within hypoxic pockets of central tumors and activation of innate immunity. Herein we have...
2.
Kim H, Choi B, Mouli S, Choi H, Harris K, Kulik L, et al.
Adv Healthc Mater
. 2023 May;
12(26):e2300906.
PMID: 37163283
Herein a practical strategy for augmenting immune activation in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is presented. Pluronic F127 (PF127) is incorporated with Lipiodol (LPD) to achieve safe...
3.
Choi B, Pe J, Yu B, Kim D
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765871
Rodent HCC rat models provide advantages for interventional oncology (IO) based immunotherapy research compared to other established larger animal models or mice models. Rapid and predictable tumor growth and affordable...
4.
Kim K, Choi B, Choi H, Ko M, Kim D, Kim D
J Nanobiotechnology
. 2022 Sep;
20(1):428.
PMID: 36175895
Ferroptosis provides an opportunity to overcome the cancer cell therapeutic resistance and modulate the immune system. Here an interaction between ferroptosis of cancer cells and natural killer (NK) cells was...
5.
Choi H, Choi B, Han J, Shin H, Park W, Kim D
Small
. 2022 Aug;
18(38):e2202694.
PMID: 35962759
A reactive oxygen species (ROS) responsive cleavable hierarchical metallic supra-nanostructure (HMSN) is reported. HMSN structured with thin branches composed of primary gold (Au) nanocrystals and silver (Ag) nano-linkers is synthesized...
6.
Pe J, Choi B, Choi H, Kwon S, Kim D
Cardiovasc Intervent Radiol
. 2022 Aug;
45(12):1834-1841.
PMID: 35962212
Purpose: To evaluate the preclinical in vivo therapeutic response of Lenvatinib-eluting microspheres (LEN-EM) transcatheter arterial chemoembolization (LEN-TACE) in an hepatocellular carcinoma (HCC) rat model. Methods: Magnetic resonance imaging (MRI) visible...
7.
Lin A, Choi B, Sim T, Yang E, Choi H, Behdad A, et al.
Blood Adv
. 2022 Jun;
6(15):4581-4592.
PMID: 35687489
In preclinical studies, we investigated a novel mechanism of in situ vaccination in lymphoma. Radiation therapy (RT) can induce abscopal responses in lymphoma models, but this has not translated into...
8.
Choi B, Kim D
Adv Nanobiomed Res
. 2022 Jun;
1(10).
PMID: 35663354
Immune checkpoint inhibitor (ICI) cancer immunotherapies are becoming one of the standard therapies for cancer patients. However, ICI cancer immunotherapy's overall response rate is still moderate and even combinational ICI...
9.
Sim T, Choi B, Kwon S, Kim K, Choi H, Ross A, et al.
ACS Nano
. 2021 Jun;
15(8):12780-12793.
PMID: 34165964
Natural killer (NK) cell-based immunotherapy has been considered a promising cell-based cancer treatment strategy with low side effects for early tumors and metastasis. However, the therapeutic efficacy is generally low...
10.
Choi H, Choi B, Yu B, Li W, Matsumoto M, Harris K, et al.
Biomaterials
. 2020 Sep;
265:120408.
PMID: 32992115
Degradable embolic agents that provide transient arterial occlusion during embolization procedures have been of interest for many years. Ideally, embolic agents are visible with standard imaging modalities and offer on-demand...